A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Ridaforolimus|DRUG: Dalotuzumab|DRUG: Exemestane
Sponsor: Merck Sharp & Dohme LLC